Page last updated: 2024-10-25

citalopram and Local Neoplasm Recurrence

citalopram has been researched along with Local Neoplasm Recurrence in 4 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen."7.76Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010)
"Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours."7.74Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2008)
" Of the 125 evaluable patients with stages II through IV HNC but without baseline depression, 60 were randomized to prophylactic antidepressant escitalopram oxalate and 65 to placebo at the time of the initial diagnosis."5.27Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( Burke, WJ; Lydiatt, WM; Panwar, A; Rieke, K; Sayles, H, 2018)
"Breast cancer patients with indications for an SSRI may be prescribed citalopram - and possibly other SSRI - without adversely affecting the outcome of adjuvant therapy with tamoxifen."3.76Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2010)
"Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours."3.74Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. ( Ahern, TP; Cronin-Fenton, D; Ewertz, M; Garne, JP; Hamilton-Dutoit, S; Lash, TL; Lunetta, KL; Pedersen, L; Rosenberg, CL; Silliman, RA; Sørensen, HT, 2008)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Panwar, A1
Rieke, K1
Burke, WJ2
Sayles, H1
Lydiatt, WM2
Lash, TL2
Pedersen, L2
Cronin-Fenton, D2
Ahern, TP2
Rosenberg, CL2
Lunetta, KL2
Silliman, RA2
Hamilton-Dutoit, S2
Garne, JP2
Ewertz, M2
Sørensen, HT2
Lazure, KE1
Denman, D1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer[NCT05724849]Phase 264 participants (Anticipated)Interventional2023-08-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for citalopram and Local Neoplasm Recurrence

ArticleYear
Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA otolaryngology-- head & neck surgery, 2018, 11-01, Volume: 144, Issue:11

    Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Double-Blind Method; Female; Head

2018
Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial.
    Head & neck, 2009, Volume: 31, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Carcinoma, Squamous Cell;

2009

Other Studies

2 other studies available for citalopram and Local Neoplasm Recurrence

ArticleYear
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Citalopram; Dr

2008
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:3

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neopl

2010